A Phase 3 interventional study of Baricitinib and Placebo in Areata Alopecia, Alopecia and Hypotrichosis, sponsored by Eli Lilly and Company. Recruiting at 127 sites in 12 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension (LTE) Period, and a 4-week Post-treatment Follow-up period. Some individuals may be eligible to receive treatment after completing the LTE, for a maximum of 180 weeks.
Current episode of severe AA of less than 8 years.
Exclusion Criteria:
Participants will receive baricitinib high dose orally.
Drug: Baricitinib
Participants will receive baricitinib low dose orally.
Drug: Baricitinib
Participants will receive placebo
Drug: Placebo
Administered orally
Also known as: LY3009104
Administered orally
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) ≤20
Time frame: Week 36
Percent Change from Baseline in SALT Score
Time frame: Baseline, Week 36
Percentage of Participants Achieving At Least 90% Improvement from Baseline (SALT90)
Time frame: Week 36
Percentage of Participants Achieving an Absolute SALT ≤10
Time frame: Week 36
Percentage of Participants with Patient Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 Among Participants 12 Years and Older with PRO for Scalp Hair Assessment Score ≥3 at Baseline
Time frame: Week 36
Mean Change from Baseline in SALT Score
Time frame: Baseline, Week 36
Percentage of Participants Achieving At Least 50% Improvement from Baseline (SALT50)
Time frame: Week 36
Percentage of Participants Achieving At Least 75% Improvement from Baseline (SALT75)
Time frame: Week 36
Percentage of Participants Achieving At Least 100% Improvement from Baseline (SALT100)
Time frame: Week 36
Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 Among Participants with CLinRO Measure for EB Hair Loss ≥2 at Baseline
Time frame: Week 36
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 Among Participants with CLinRO Measure for EL Hair Loss ≥2 at Baseline
Time frame: Week 36
Percentage of Participants Achieving PRO Measure for EB 0 or 1 (Among Participants 12 Years or Older with PRO Measure for EB ≥2 at Baseline)
Time frame: Week 36
Percentage of Participants Achieving PRO Measure for EL 0 or 1 (Among Participants 12 Years or Older with PRO Measure for EL ≥2 at Baseline)
Time frame: Week 36
Mean Change from Baseline in Hospital Anxiety Depression Scale (HADS)
The HADS is a participant-rated instrument used to assess both anxiety and depression and is available in a pediatric self-report for participants ≥12 years old. This instrument consists of 14 item questionnaires, each item is rated on a 4-point scale. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression.
Time frame: Week 36
Mean Change from Baseline in Patient-Reported Outcome Measurement Information System (PROMIS) Anxiety Score
The PROMIS Anxiety Short Form (8 questions, 8a v2.0) is available in a pediatric self-report (ages 8 to \<18 years) and for parents/caregivers serving as proxy reporters for their children (youth ages ≥5 years). Both pediatric self-report and proxy-report versions assess anxiety "in the past seven days". Response options range from 1 = Never; 2 = Rarely; 3 = Sometimes; 4 = Often; to 5 = Almost always. Total raw scores are converted to T-Scores with higher scores representing greater anxiety.
Time frame: Baseline, Week 36
Mean Change from Baseline in PROMIS Depression Score
The PROMIS Depression Short Form (8a v2.0 and 6a v2.0) is available in a pediatric self-report (ages 8 to \<18 years) and for parents/caregivers serving as proxy reporters for their children (youth ages ≥5 years). Both pediatric self-report and proxy-report versions assess depression "in the past seven days." Response options range from 1 = Never; 2 = Rarely; 3 = Sometimes; 4 = Often; to 5 = Almost always. Total raw scores are converted to T-Scores with higher scores representing greater depression.
Time frame: Baseline, Week 36
Mean Change from Baseline in PROMIS Peer Relationship Score
The PROMIS Peer Relationships Short Form planned to be used in the study measures 2 aspects of social functioning, friendship quality and peer acceptance, and is available in a pediatric self-report (ages 8 to \<18 years) and for parents/caregivers serving as proxy reporters for their children (youth ages 5 to \<8 years).
Time frame: Baseline, Week 36
Mean Change from Baseline in Family Dermatology Life Quality Index (FDLQI)
The FDLQI is a 10-item validated questionnaire designed for adult (\>16 years old) family members of participants. The questionnaire is completed by family members of the AA participants (for example, parents/caregivers) and measures the secondary impact of the participant's skin disease on family QoL. Response categories include "not at all/not relevant," "only a little," "quite a lot," and "very much," with corresponding scores of 0, 1, 2, and 3, respectively, with unanswered ("not relevant") responses scored as 0.
Time frame: Baseline, Week 36
Pharmacokinetics (PK): Maximum Concentration (Cmax)
Time frame: Baseline through Week 36
PK: Area Under the Concentration Curve (AUC)
Time frame: Baseline through Week 36
Change of Immunoglobulin G (IgG) Titers
Time frame: Pre-Vaccination to 4 Weeks and 12 Weeks Post-Vaccination
Showing the first 100 of 127 sites across 12 countries.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Sap, Csr
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company